Diethylamine-Chromocarbo, a flavonic derivative has been shown to exert a protective action on capillary endothelium and inhibits aldose-reductase activity, which are known to be important factors in pathogenesis and prognosis of the chronic complications of the diabetes.
Indeed, there are some reports which support that diethylamine-chromocarbo has favorable effects on the diabetic retinopathy and neuropathy, but few on nephropathy.
This study has attempted to evaluate the effect of diethylamine-chromocarbo on the renal function of the patients with type Ⅱ diabetes mellitus.
Diethylamine-chromocarbo was given at a dosage of 200㎎ t.i.d. randomly. Oral GTT, funduscopy and 24 hours urinary protein excretion with creatinine clearance were evaluated every 6 months for 3 years. To avoid the deteriorative effects from poor diabetic control on the renal function, only the result of 113 patients were analysed, whose blood sugar, lipids and HbA, has remained within normal limit during study period from months after initiation of the treatment. Among them 50 were given diethylamine-chromocarbo and 63 were served as control. Patients were further sub-divided into 3 different severity groups according to their results of initial studies.
Comparing the prognosis between treated and untreated group, diethylamine-chromocarbo showed benificial effect on the retinopathy and nephropathy.
This difference in the prognosis dose not very well co-related with initial degree of glucose intolerance nor retinal impairment, but the degree of renal function, being most prominant in mildly impaired group. Namely, in the group whose renal function was mildly imparied initially, 5 out of 29 chromocarbo treated group improved and their renal function restored to normal while only one out of 15 control restored. On the otherhand, the renal complication has progressed in one out of 29 treated, while 3 out of 15 control, progressed. No serious side effects was observed during the treatment.
With this result, we concluded that diethylamine-chromocarbo is effective on early developing lesions and clinically safe and can be used to treat diabetic nephropathy in a hope to prevent and ameliorate its caurse, even in advanced nephropathy, to prevent from further progression.
|